Fiche centre
Princess Margaret Cancer Center
Toronto — Canada
Essais liés4clinical trials
VilleTorontolocalisation
PaysCanadalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05086692
Essais cliniques associés
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ipatasertib | Cancer | Phase 3 | NCT05862285 | UmbrellaMAX — A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study | RECRUITING |
| MDNA11 | Cancer | Phase 1/2 | NCT05086692 | ABILITY-1 — A Beta-only IL-2 ImmunoTherapY Study | ACTIVE_NOT_RECRUITING |
| Giredestrant | Cancer | Phase 3 | NCT06065748 | A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | ACTIVE_NOT_RECRUITING |
| Obinutuzumab | Cancer | Phase 3 | NCT06084936 | GLOBRYTE — A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | RECRUITING |